Treatment with imatinib is associated with an excellent prognosis in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia in first chronic phase. Secondary resistance is rather rare, but occurs predominantly within the first year of diagnosis. Resistance is associated with PDGFRA kinase domain mutations that are sensitive in vitro to second-generation tyrosine kinase inhibitors, but these compounds seem to have limited activity in clinical practice. Because of an aggressive clinical course and lack of alternative conventional treatment options, allogeneic stem cell transplantation should be performed in eligible patients, as it might be the only effective and curative treatment option.
The Baltic Sea, which connects middle, northern and eastern European countries, is the setting for an exciting new stem cell conference, the Baltic Stem Cell Meeting. Cold in winter, but glorious in summer, the Baltic coast will be the place where, every 2 years, researchers from all over the world, possessed by the fever of stem cell research, will come together. Besides the pleasant summer temperature, it is no coincidence that stem cell research in this part of world has a long history. It was in St Petersburg that Alexander Maximow first coined the term 'stem cell'. After demonstrating that all blood cells develop from a common precursor cell, Maximow proposed the unitarian theory of hematopoiesis. His experimental work provided evidence, confirming that lymphocytes of the blood and lymph nodes are undifferentiated cells with stem cell properties. 1 A few decades earlier, at the opposite side of the Baltic in western Pomerania (at that time part of Prussia), Rudolf Virchow, the father of cellular pathology, was born. He is also cited as the first pathologist to recognize leukemia cells and proposed the famous epigram 'Omnis cellula e cellula' (every cell originates from a similar existing cell). He and his trainee, Julius Cohnheim, who was also born close to the Baltic coast in western Pomerania, proposed the embryonic rest hypothesis of cancer development, a concept that laid the groundwork for the currently popular theory in which cancer is described as a stem cell disorder. 2 In more modern times, other excellent stem cell researchers, including Dr Sven Age Killmann (a founder of our journal Leukemia), have also worked in the Baltic region in Copenhagen. Dr Killmann, together with his wife (Dr Nicole Killmann, editor of Leukemia), coined the sleeper-feeder theory for leukemia. Accordingly, it has been proposed that malignancies in the hematopoietic system seem to depend on a small subset of so-called cancer stem cells for their continued growth and progression.
This first Baltic Stem Cell Meeting was held in Szczecin, the capital of Western Pomerania, Poland, and was sponsored by an economic innovation grant awarded by the European Union and supported by the Polish Ministry of Science. The host of the meeting was Pomeranian Medical University.
Nearly 50 lectures were presented by top stem cell researchers from nearly every continent. The major scientific topics of this meeting were clinical applications of adult tissue-and umbilical cord blood-derived stem cells in regenerative medicine, the biological significance of the presence of very small embryonic like stem cells (VSELs) in adult tissues, regulation of stem cell trafficking, mechanisms of malignant transformation of cells and mechanisms of unconventional exosome-or microparticle-based cell-to-cell communication.
In addition to these scientific topics, several important legal and ethical issues concerning stem cell research were also discussed.
Two opening lectures on the state of the art of their respective fields were presented by Dr Mortimer Poncz, who gave an overview of the role of chemokines in megakaryopoiesis, and by Dr Peter Quesneberry, who presented an original hypothesis in which the stem cell compartment is described as a continuum of cycling cells that continuously change phenotype. During the following sessions, several investigators, including Dr Arnon Nagler (Israel), Dr Torsten Tonn (Germany), Dr Barbara Lukomska (Poland), Dr Kyung-Sun Kang (Korea) and Dr Cai Dongqing (China), presented exciting data on potential applications of umbilical cord blood as a source of stem cells for regeneration of neural tissues and myocardium. Dr Yoshiaki Sonoda (Japan) described a rare population of umbilical cord blood CD34-negative hematopoietic stem cells that are endowed with remarkable hematopoietic potential after intrabone injection.
3 Dr Maciej Kurpisz (Poland) presented interesting data on the application of skeletal myoblasts in the treatment of heart infarct, and Dr Chris Hawkey (UK) reported positive results for bone marrow transplants in patients suffering from Crohn 0 s disease. 4 Dr Jan Nolta (USA) provided an update on the clinical research initiative currently running at the University of California (Davis, CA, USA).
Another exciting series of lectures addressed the biological significance of VSELs in adult tissues. Dr Diane Krause (USA) presented data showing that VSELs are endowed with the potential to regenerate damaged lung epithelial cells, and Dr Irma VirantKlun (Slovakia) presented evidence for the presence of VSELs in postmenopausal ovaries. 5 Dr Mariusz Ratajczak (USA) presented an update on VSEL research, with special emphasis on hematopoietic differentiation of these cells 6 and their role in aging. 7, 8 Novel evidence was also presented about mobilization of these cells in patients with colitis ulcerosa and skin burns. The lecture by Dr Wojtek Wojakowski (Silesian Medical University, Poland) focused on a clinical trial with VSEL infusion in patients with heart infarct. The potential application of VSELs and umbilical cord blood-derived cells in regenerative medicine was the topic of a business panel conducted by Drs Alan Harris and Denis Rodgerson (USA) and Dr Nicholas Zech (Austria).
A series of excellent lectures was devoted to the mechanisms that regulate stem cell trafficking. Lectures on the state of the art were presented by Dr Tsvee Lapidot (Israel), Dr Anna JanowskaWieczorek (Canada) and Dr Jun Yan (USA). In these lectures, the emerging roles of the complement cascade, innate immunity, 9,10 the nervous system, and bioactive lipids 9,11 in stem cell mobilization and homing were described. The endothelial niche and new strategies for its visualization 12 were presented in an excellent lecture presented by Dr Edward Scott (USA).
An exciting stem cell meeting cannot be organized without also hearing from leading hematologists. Professor Donald Miller (USA) presented a novel approach to killing cancer cells by employing genomic-directed DNA fragments (aptamers). Professor Alicja Chybicka (Poland) presented exciting data on extracorporeal photophoresis for salvage therapy of graft-versushost disease, and Professor Hans Jochen-Kolb (Germany) gave an overview of mechanisms of graft-versus-host disease after allogeneic stem cell transplantation.
A few interesting lectures were devoted to mesenchymal stem cells. Dr Andrzej Lange (Poland), Dr Claudia Land and Dr Axel Zander (Germany), Dr Ewa Sikora (Poland) and Dr Guenther Lepperdinger (Austria), discussed clinical aspects of mesenchymal stem cell transplantation, the role of these cells in tissue/organ repair, and molecular mechanisms that regulate their aging.
A special session to address the growing role of microvesicles/ exosomes in cell-to-cell communication and tissue regeneration was also organized. The topic of microparticles was discussed during the opening lecture by Dr Peter Quesneberry, and the role of mesenchymal stem cell-derived microvesicles in regeneration of kidney was the subject of an excellent lecture by Dr Giovanni Camussi (Italy).
In addition to these scientific topics, several crucial legal and ethical issues concerning stem cell research were discussed. Reverend Tomasz Trafny presented the Vatican's overview on ethics in science and stem cell research, and was followed by Dr Andrzej Gorski, Vice President of the Polish Academy of Science, who addressed important ethical issues in science.
The meeting was judged by all the participants to be a great success and an important step toward integrating stem cell research in Baltic countries. Thus, the Baltic, which divided countries 20 years ago, has become an inner lake of the European Union and now connects East and West. Please join us for the 2nd Baltic Stem Cell Meeting in 2013.
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The author declares no conflict of interest. Clinical value of flow cytometric immunophenotypic analysis for minimal residual disease detection in autologous stem-cell products of follicular and mantle cell lymphomas Graft purging can translate into more durable disease remission in patients with follicular lymphoma (FL) and mantle cell lymphoma (MCL). Currently, polymerase chain reaction (PCR) is the most widely used technique for assessment of minimal residual disease (MRD) during and after treatment. However, maximally 40-60% of the t(11;14) breakpoints or clonal immunoglobulin rearrangement in MCL can be detected using consensus PCR primers, 1,2 and there is no worldwide standard protocol to evaluate MRD in hematopoietic stem-cell products. For exploration of a broadly sensitive assay, we conducted a retrospective study to evaluate usefulness and clinical value of flow cytometric immunophenotyping (FCM) to detect MRD in stem-cell products of FL and MCL.
Subjects were 30 patients (19 FL and 11 MCL) undergoing autologous stem-cell transplantation (ASCT) in our institute. Patient characteristics were given in Table 1 . They were diagnosed as advanced stage diseases with bone marrow/peripheral blood involvement. All patients had available FCM data before pretransplant induction chemotherapy and of stem-cell grafts.
Surface immunophenotyping of the B cells was performed using the following panel of lymphoid-associated monoclonal antibodies: fluorescein isothiocyanate/phycoerythrin/peridin chlorophyll protein yanine5.5/allophycocyanin labeled CD5 (Becton, Dickinson and Company (BD), Mountain View, CA, USA), CD10 (BD), CD19 (BD), CD20 (BD) and surface immunoglobulin (BD). Immunophenotypic detection was performed by three-color FCM. Multiparameter analysis of gated cell populations during cell suspension studies was performed to yield more definitive immunophenotypic information using CELLQuest software (BD). A total of 15 000 events were acquired in each panel. If samples contained viable cell number o15 000, the events acquired by the cytometer varied from sample to sample. For analysis, lymphocytes, monocytes and granulocytes were gated by forward vs side scatter. B lymphocytes were designated by CD19 gating in addition to forward and side scatter. Clonal B-cell expansion was detected by light chain-restricted B-cell markers. Using this method, the maximum sensitivity of FCM was 1.5 Â 10 À4 (data not shown). Figures 1a and b showed the typical examples for gating to assess lymphoma involvement. All 30 patients could obtain enough samples of stem-cell products and could be evaluated with this protocol. The negativity of tumor cell contamination (o0.01%) in grafts was confirmed in all patients.
DNA was extracted from mononuclear cells using QIAamp DNA Mini Kit (QIAGEN GmbH, Hilden, Germany) according to the manufacturer's instructions. Semi-nested PCR was carried 
